FCM
KRTX

Farallon Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Farallon Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-522,000
Closed -$165M – 190
2023
Q4 		$165M Buy
522,000
+519,800
+23,627% +$101M 0.76% 37
2023
Q3 		$372K Hold
2,200
– – ﹤0.01% 121
2023
Q2 		$477K Hold
2,200
– – ﹤0.01% 129
2023
Q1 		$400K Hold
2,200
– – ﹤0.01% 152
2022
Q4 		$432K Sell
2,200
-77,800
-97% -$16.7M ﹤0.01% 180
2022
Q3 		$18M Sell
80,000
-20,000
-20% -$4.05M 0.1% 101
2022
Q2 		$12.7M Sell
100,000
-250,000
-71% -$28.7M 0.07% 120
2022
Q1 		$44.4M Sell
350,000
-200,000
-36% -$22.5M 0.21% 74
2021
Q4 		$72M Sell
550,000
-150,000
-21% -$19.4M 0.36% 54
2021
Q3 		$85.6M Buy
700,000
+70,000
+11% +$8.08M 0.4% 58
2021
Q2 		$71.8M Sell
630,000
-45,000
-7% -$5.26M 0.29% 60
2021
Q1 		$81.2M Sell
675,000
-25,000
-4% -$2.83M 0.4% 54
2020
Q4 		$71.1M Hold
700,000
– – 0.43% 56
2020
Q3 		$54.1M Buy
700,000
+125,000
+22% +$10.7M 0.37% 61
2020
Q2 		$64.1M Buy
575,000
+7,953
+1% +$691K 0.51% 51
2020
Q1 		$40.8M Sell
567,047
-32,953
-5% -$2.82M 0.35% 50
2019
Q4 		$45.2M Buy
+600,000
New +$26.3M 0.31% 59

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Farallon Capital Management's KRTX Position: Q1 2024 in Review

Farallon Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 522,000 shares — an estimated $165M sold.

Farallon Capital Management first reported a position in KRTX in Q4 2019 and held it in 17 quarters. The position peaked at $165M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Farallon Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Farallon Capital Management sold 522,000 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $165M.
  • Farallon Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 17 quarters.
  • Farallon Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $165M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Farallon Capital Management's 13F filing for Q1 2024, filed 15 May 2024.